Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients.

ABSTRACT:

Background and aims

COPD is a common chronic condition in older age that impacts on daily activities and quality of life. Previous studies suggest that magnesium deficit in COPD patients affects bronco-obstruction, inflammation, and physical performance. We investigated whether oral magnesium supplementation in stable-phase COPD patients improves lung function, physical performance, and quality of life.

Methods

We conducted a double-blind randomized-controlled clinical study with 49 participants divided into two groups: one given 300 mg/day of magnesium citrate (n = 25) and the other one sachet/day of a placebo (n = 24). The following parameters were assessed at baseline and after 3 and 6 months: lung function (spirometry), physical performance (handgrip strength, lower limb

SUBMITTER: Zanforlini BM 

PROVIDER: S-EPMC8794984 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature